medigraphic.com
ISSN 0188-2198 (Print)

2009, Number 3

<< Back Next >>

Rev Mex Cardiol 2009; 20 (3)

Effect of cardiac resynchronization therapy on the levels of PCN and IL-10 in patients with dilated cardiomyopathy

Garibay-Guzmán FJ, Robledo-Nolasco R, Montaño-Estrada LF, Aceves-Chimal JL

Language: Spanish
References: 20
Page: 121-125
PDF size: 79.76 Kb.


ABSTRACT

Dilated myocardiopathy produce damage in the miocite, interstice or both, increasing pro- inflammatory cytokines and effects with cardiac asynchronism. The Cardiac Resynchronization Therapy improvement left ventricular function and reduce cardiac remodelation. We evaluated the effect of this therapy on PNB and IL-10 levels.
Material and methods: We included patients with dilated myocardiopathy that underwent to CRT. Patients that rejected the therapy were considered as controls. We determine Natriuretic Peptide Brain and Interleukin 10 basal and 30 days. We Registered age, sex, cardiovascular risk factors, walking 6 minutes test and functional class. We used statistical package SPSS 16.0 for Windows and considered statistical significance with p ‹ 0.05.
Results: We analyze 14 patients. Ten patients underwent to CRT and 4 to control group. Female were 14 patients (Case group n = 6 and control group n = 4). All patients in CRT group showed improvement in functional class (NYHA III to I n = 6 and II to I n = 4) and in tolerance walking 6 minute test, while control group did not showed any change. The PNB levels showed significant reduction in CRT group (p ‹ 0.001) and IL10 elevation without significant difference between both groups.
Conclusion: The Cardiac Resynchronization Therapy reduces PNB levels, increase IL-10. improvement functional class and tolerance to physic exercice in patients with dilated cardiomyopathy and cardiac asynchronism.


REFERENCES

  1. Lewis LP. Heart failure. Self study program. 2005.

  2. Mariell J. Heart failure. N Engl J Med 2003; 348: 2007-2018.

  3. Rivera M. Myocardial remodeling and immunologic activation in patients with heart failure. Rev Esp Cardiol 2006; 59(9): 911-918.

  4. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358: 2148-2159.

  5. Morrow DA, de Lemos JA. Benchmarkers for the assessment of novel cardiovascular biomarkers. Circulation 2007; 115: 949-952.

  6. Anker SD, von Haehling S. Inflammatory mediator in chronic heart failure: an overview. Heart 2004; 90: 464-470

  7. Lee DS, Vasan RS. Novel markers for heart failure diagnosis and prognosis. Curr Opin Cardiol 2005; 20: 201-210.

  8. Knut, Lappega RD, Hanne B. Antiinflammatory effect of cardiac resynchronization therapy. PACE 2006; 29: 753-758.

  9. Theodorakis GN. Antiinflammatory effects of cardiac resynchronization therapy in patients with chronic heart failure. PACE 2006; 29: 255-261.

  10. Bax JJ. Cardiac resynchronization therapy part 1. Issues before device implantation. J Am Coll Cardiol 2005; 46: 2153-2167.

  11. Linde C, Braunschweig F, Gadler F. Long term improvements in quality of life by ventricular pacing in patients with chronic heart failure: results from the multisite stimulation in cardiomyopathy study (MUSTIC). Am J Cardiol 2003; 91: 1090-1095.

  12. Abraham WT, Fisher WG, Smith AL. Cardiac CTR in chronic heart failure. N Engl J Med 2002; 346: 1845-1853.

  13. Strickberger SA. Patient selection for cardiac resynchronization therapy. Circulation 2005; 111: 2146-2150.

  14. M.isabel Sá et al. Imaging techniques in cardiac resynchronization therapy. Int J Cardiovasc Imaging 2008; 24: 89-105

  15. Butter C, Auricchio A, Stellbrink C. Effects of resynchronization therapy stimulation site on the systolic function of heart failure patients. Circulation 2001; 104: 3026-3029.

  16. Butter C, Auricchio A, Stellbrink C. Effects of resynchronization therapy stimulation site on the systolic function of heart failure patients. Circulation 2001; 104: 3026-3029.

  17. Strickberger SA. Patient selection for cardiac resynchronization therapy. Circulation 2005; 111: 2146-2150.

  18. Suárez. Citocinas y quimiocinas. Nat Rev Inmunol 2007: 11: 1-20.

  19. Anker SD, von Haehling S. Inflammatory mediator in chronic heart failure: an overview. Heart 2004; 90: 464-470

  20. Yamaoka M. Antiinflammatory cytokine profile in human heart failure: behavior of IL-10 in association with FNTa. Jpn Circ J 1999; 63: 951-956.




2020     |     www.medigraphic.com